Mobile

A 6-week International, Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustain...

Update Il y a 5 ans
Reference: EUCTR2004-000912-13

A 6-week International, Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study to Evaluate the Feasibility of Switching from Immediate-release Quetiapine Fumarate (SEROQUEL) to Sustained-release Quetiapine Fumarate (400 to 800 mg/day) in Outpatients with Schizophrenia

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objectives is to demonstrate that the efficacy of the sustained release formulation (SR) of quetiapine is not inferior to the immediate release formulation (IR).

Inclusion criteria

  • Schizophrenia

Links